384 related articles for article (PubMed ID: 34393104)
1. Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.
Panopoulos ST; Tektonidou MG; Bournia VK; Arida A; Sfikakis PP
J Rheumatol; 2022 Jan; 49(1):68-73. PubMed ID: 34393104
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.
Gernert M; Tony HP; Fröhlich M; Schwaneck EC; Schmalzing M
Front Immunol; 2021; 12():817893. PubMed ID: 35111167
[TBL] [Abstract][Full Text] [Related]
3. Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A; Walker KM; Pope JE;
Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort.
Windirsch K; Jordan S; Becker MO; Bruni C; Dobrota R; Elhai M; Garaiman IA; Mihai CM; Iudici M; Hasler P; Ribi C; Maurer B; Gabrielli A; Hoffmann-Vold AM; Distler O
Swiss Med Wkly; 2024 Feb; 154():3630. PubMed ID: 38579324
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study.
Adrovic A; Yildiz M; Haslak F; Koker O; Aliyeva A; Sahin S; Barut K; Kasapcopur O
Rheumatol Int; 2021 Jan; 41(1):121-128. PubMed ID: 33108799
[TBL] [Abstract][Full Text] [Related]
7. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
[TBL] [Abstract][Full Text] [Related]
8. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
10. Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy.
Shima Y; Kawaguchi Y; Kuwana M
Mod Rheumatol; 2019 Jan; 29(1):134-139. PubMed ID: 29529897
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
12. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
13. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
Shima Y; Hosen N; Hirano T; Arimitsu J; Nishida S; Hagihara K; Narazaki M; Ogata A; Tanaka T; Kishimoto T; Kumanogoh A
Mod Rheumatol; 2015 Jan; 25(1):134-7. PubMed ID: 24533556
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Kivitz A; Olech E; Borofsky M; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Rowell L; Nasmyth-Miller C; Bao M; Wright S; Pope JE
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
Smolen JS; Avila JC; Aletaha D
Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Elhai M; Boubaya M; Distler O; Smith V; Matucci-Cerinic M; Alegre Sancho JJ; Truchetet ME; Braun-Moscovici Y; Iannone F; Novikov PI; Lescoat A; Siegert E; Castellví I; Airó P; Vettori S; De Langhe E; Hachulla E; Erler A; Ananieva L; Krusche M; López-Longo FJ; Distler JHW; Hunzelmann N; Hoffmann-Vold AM; Riccieri V; Hsu VM; Pozzi MR; Ancuta C; Rosato E; Mihai C; Kuwana M; Saketkoo LA; Chizzolini C; Hesselstrand R; Ullman S; Yavuz S; Rednic S; Caimmi C; Bloch-Queyrat C; Allanore Y;
Ann Rheum Dis; 2019 Jul; 78(7):979-987. PubMed ID: 30967395
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
19. Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels.
Kuzumi A; Ebata S; Fukasawa T; Matsuda KM; Kotani H; Yoshizaki-Ogawa A; Sato S; Yoshizaki A
JAMA Dermatol; 2023 Apr; 159(4):374-383. PubMed ID: 36790794
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
